Nanomedicines in the treatment of emesis during chemotherapy: focus on aprepitant

Figures & data

Figure 1 Aprepitant’s active chemical structure.

Figure 2 Aprepitant nanomilling flow schematic.

Table 1 Key randomized studies with aprepitant

	Poli-Bigelli et al 2003		Hesketh et al 2003		Warr et al 2005
No. patients	569		530		866
Chemotherapy	Cisplatin		Cisplatin		Anthr + Cyclo
CR rates	NK1 vs control		NK1 vs control		NK1 vs control
Acute vomiting % (Day 1)	82.8	68.4	89.2	78.1	88	77
Delayed vomiting % (Days 2–5)	67.7	46.8	74.4	55.8	81	69
Overall control % (Days 1–5)	62.7	43.3	72.7	52.3	51	42

Abbreviations: Anthr, anthracycline; Cyclo, cyclophosphamide; NK1, neurokinin 1 receptor.

Poli-BigelliSRodrigues-PereiraJCaridesAD2003Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: results from a randomized, double-blind, placebo-controlled trial in Latin AmericaCancer973090812784346

 PubMed Web of Science ®Google Scholar

HeskethPJGrunbergSMGrallaRJ2003The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patient receiving high-dose cisplatin. The aprepitant protocol 052 study groupJ Clin Oncol2141121914559886

 PubMed Web of Science ®Google Scholar

WarrDGHeskethPJGrallaRJ2005Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapyJ Clin Oncol2328223015837996

 PubMed Web of Science ®Google Scholar